Oncohema Key

CONCLUSIONS Part of “CHAPTER 121 – ENDOCRINE ASPECTS OF BENIGN PROSTATIC HYPERPLASIA“

ANDROGEN DEPRIVATION THERAPY Part of “CHAPTER 121 – ENDOCRINE ASPECTS OF BENIGN PROSTATIC HYPERPLASIA“ Although the exact pathogenesis of BPH is not well defined, clearly aging and the presence of…

ENDOCRINE ASPECTS OF BENIGN PROSTATIC HYPERPLASIA Elizabeth A. Miller William J. Ellis Benign prostatic hyperplasia (BPH) is a common disorder of the aging male that is a benign enlargement of…

TREATMENT Part of “CHAPTER 120 – GYNECOMASTIA“ The treatment of gynecomastia depends on the underlying cause. Surgical removal of estrogen-producing or hCG-producing tumors usually is required and may be curative….

EVALUATION OF THE PATIENT WITH GYNECOMASTIA Part of “CHAPTER 120 – GYNECOMASTIA“ The evaluation should focus initially on identifying patients in whom the breast enlargement is a manifestation of a…

CAUSES OF GYNECOMASTIA Part of “CHAPTER 120 – GYNECOMASTIA“ PHYSIOLOGIC GYNECOMASTIA Physiologic gynecomastia can be seen at the extremes of life. Neonatal gynecomastia usually is transient, reflecting the effect of…

HORMONAL CONTEXT OF GYNECOMASTIA Part of “CHAPTER 120 – GYNECOMASTIA“ Given the long-recognized role of estrogens in stimulating mammary growth, it is not surprising that high circulating estrogen levels of…

GENERAL CONSIDERATIONS Part of “CHAPTER 120 – GYNECOMASTIA“ Gynecomastia (enlargement of the male breast secondary to an increase in glandular tissue and stroma) can be a vexing clinical problem.1,2 and…

GYNECOMASTIA Allan R. Glass GENERAL CONSIDERATIONS HORMONAL CONTEXT OF GYNECOMASTIA

ANTIANDROGENS Part of “CHAPTER 119 – CLINICAL USE AND ABUSE OF ANDROGENS AND ANTIANDROGENS“ Antiandrogens are drugs that antagonize the actions of androgens by binding to or interacting with androgen…